4D Molecular Therapeutics reports positive interim data for 4D-150 in wet AMD and DME, with strong financial position and strategic focus. 4D Molecular Therapeutics announced positive interim data for ...

Oculis Holding AG announced that the final patient visit has been completed in the DIAMOND phase 3 program assessing OCS-01, ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of ...

Image source: The Motley Fool. EyePoint Pharmaceuticals (NASDAQ:EYPT) advanced its lead candidate, DuraVu, through rapid phase 3 enrollment in wet AMD and aligned phase 3 DME trial initiation while ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ...

Please provide your email address to receive an email when new articles are posted on . EyePoint Pharmaceuticals has announced positive 16-week data from the ongoing phase 2 VERONA trial evaluating ...

Investing.com -- Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) tumbled 21% following the release of positive ...

New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DMEKey data for Susvimo demonstrate its potential to ...

President and Chief Executive Officer — Jay S. Duker, M.D. Chief Financial Officer — George O. Elston Chief Medical Officer — Ramiro Ribeiro, M.D. Management expects DuraVu to be the only tyrosine ...